TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01219413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren, Perindopril
Description: Rasilez 300 mg Prestarium 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren, Perindopril
Description: Rasilez 300 mg Prestarium 10 mg
Study: NCT04252898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Front-of-pack nutrition label Nutri-Score
Description: The intervention consists of displaying the Nutri-Score on dishes and pre-packed foods.
Study: NCT03996642

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Avatar Life Review
Description: VoicingHan will screen-capture patient's storytelling performances as video files. Immediately before the first intervention, patients will complete an array of self-reported questionnaires to assess physical, spiritual, and psychological well-being and elicit relevant demographic and medical information. The assessments include the ESAS, FACIT-Sp subscale, and EORTC PAL 15. Subsequent administration of these questionnaires spaced 2-4 weeks apart will occur before each avatar session (pre-intervention). This will determine if intensity of the patient's symptoms have changed over the course of the intervention. Following completion of the Avatar session, a member of the research team will conduct a semi-structured, open-ended interview to assess patients' perception of intervention components and identify possible factors influencing intervention feasibility and any technical barriers.
Study: NCT04060719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 894416
Description: tablet
Study: NCT00241878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teacher-Delivered Weight Control Intervention
Description: The teacher-delivered weight control intervention (TD-WCI) is implemented over 14 weeks with three lessons per week. Many lessons include the use of colorful, friendly, hand-made puppets that represent the seven food groups of the food pyramid (Miss Grain, Miss Fruit, Mr. Vegetable, Mr. Protein, Miss Dairy, Mr. Fat and Miss Sugar). Please see Appendix IX for complete curriculum and pictures of puppets. There are three 40-minute lessons per week that consist of a 15-20 minutes interactive healthy eating and exercise didactic session and then 20 minutes of ongoing physical activity (5 minutes warm-up, 15 minutes aerobic activity composed of a number of games and dances with music, 5 minutes cool-down). In addition to the child-based curriculum the WCI has parent newsletters. These newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Teacher-Delivered General Health Intervention
Description: The teacher-delivered general health intervention (TD-GHI) serves as the control group in the proposed study. TD-GHI is a general health intervention that is similar in structure and length to TD-WCI. Topics include those related to general health and safety, such as car safety, being a good friend, poison safety, disease prevention, etc. An example of an activity is the 911 emergency call. The children learn what 911 is and what would be an appropriate call. They then practice calling 911 on play telephones and relating the important information: nature of the emergency, their name, their address, etc. They learn also to stay on the phone with the 911 dispatcher until someone comes to help them. In addition to the child-based curriculum the GHI has parent newsletters. Like TD-WCI these newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
Study: NCT02692313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Dose response of epinephrine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Dose response of epinephrine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Dose response of epinephrine infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline infusion
Description: Placebo
Study: NCT04060719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: tablet
Study: NCT05177874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traumacel FAM Trium
Description: Absorbable Hemostat (oxidized non-regenerated cellulose)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgicel Fibrillar
Description: Absorbable Hemostat (oxidized regenerated cellulose)
Study: NCT01021358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
Study: NCT02337686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03402932

Intervention type: OTHER
Group type: OTHER
Intervention: Auditory unamplified
Description: The cognitive test will be administered by using a generic presentation level that simulates a normal conversational level.
Study: NCT02337686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT00567866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: 50 or 100 mg of quetiapine orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: 50 or 100 mg of quetiapine orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: 50 or 100 mg of quetiapine orally
Study: NCT02337686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study: NCT01743612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser speckle contrast imaging
Description: blood flow recording during 30 minutes after 2 post-occlusive hyperaemia of 5 minutes separated by 30 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser speckle contrast imaging
Description: blood flow recording during 30 minutes after 2 post-occlusive hyperaemia of 5 minutes separated by 30 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser speckle contrast imaging
Description: blood flow recording during 30 minutes after 2 post-occlusive hyperaemia of 5 minutes separated by 30 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cooling
Description: blood flow of the hand recording during 30 minutes in a cooling-box

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cooling
Description: blood flow of the hand recording during 30 minutes in a cooling-box

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cooling
Description: blood flow of the hand recording during 30 minutes in a cooling-box
Study: NCT01964378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cebranopadol
Description: Participant will take one or two tablet(s) of cebranopadol in the morning and one or two placebo double-dummy morphine-like capsule(s) in the morning and the evening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Prolonged Release
Description: Participant will take one or two morphine capsule(s) in the morning and in the evening and one or two placebo double-dummy cebranopadol-like tablet(s) in the morning.
Study: NCT01619761

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic umbilical cord blood transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic umbilical cord blood transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01619761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Killer Cell Therapy
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Killer Cell Therapy
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo allogeneic umbilical cord blood transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo allogeneic umbilical cord blood transplant
Study: NCT03751371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training with HWA device
Description: Gait assessments will be conducted on participants randomized to the Trained group first during unassisted walking followed by HWA-assisted walking. Participants randomized to the Trained group will receive physical therapist supervised home and community-based walking training wearing the HWA device 2 times per week for 45-60 minutes for 8 weeks. Training will consist of walking in and outside of the home while encouraging larger and more symmetrical steps with practice of activities that challenge the person's balance and motor control. Rest breaks will be allowed as needed. If the therapist is unable to adjust the HWA to provide a safe gait pattern, the session will be ended and the device removed.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: The Untrained group will continue their usual daily activities including any exercise regimen that they typically perform. However, they will be asked not to start any new exercise program during the study period.
Study: NCT02477488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Administration of allopurinol is changed to bedtime (hs) for each patient, at the same dosage as was previously prescribed.
Study: NCT01433406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Study: NCT03269773

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FURESTEM-AD Inj.
Description: 0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5 mL).~Treatment group: FURESTEM-AD® inj. 5.0 X 107 cells/1.5 mL

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5mL)
Study: NCT00625586

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RAV12
Description: RAV12 at 0.375 mg/kg weekly escalated to 0.75 mg/kg weekly, intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 weekly, intravenously
Study: NCT00148031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon and Ribavirin
Description: Both groups with receive the same medical intervention but offered at different locations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon and Ribavirin
Description: Both groups with receive the same medical intervention but offered at different locations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial
Description: Assessment of the likelihood of HCV treatment initiation and completion

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial
Description: Assessment of the likelihood of HCV treatment initiation and completion

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-site (MMT Clinic) HCV evaluation and treatment
Description: Standard HCV treatment with Pegylated Interferon and Ribavirin

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Off-site HCV evaluation and treatment
Description: Standard HCV treatment with Pegylated Interferon and Ribavirin
Study: NCT03652389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MJS Diabetes
Description: patients will receive and respond to daily PRO (patient recorded outcomes) via text messages and report SMBG (self monitoring blood glucose), if insulin dependent, over the course of a 12 month period. They will also receive feedback and motivational messages based on patterns of their PROs
Study: NCT00838812

Intervention type: DRUG
Group type: OTHER
Intervention: application of the topic gel
Description: Clindamycin Phosphate 1,2% and tretinoin 0,025% gel once daily at night 12 weeks.
Study: NCT04352543

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Video Game Exercise
Description: Play during 30 minutes in the easy level

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill walking exercise
Description: 30 minutes (65 - 75% heart rate maximal)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary Behavior
Description: Quiet Rest: 30 minutes
Study: NCT01116388

Intervention type: OTHER
Group type: OTHER
Intervention: GFCF product with GFCF diet
Description: Group I: will receive the test product (product free of gluten and casein) with GFCF Diet for the 1st 6-weeks.~Group II: will receive the test product (product free of gluten and casein) with GFCF diet for the 2nd 6-weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: product containing gluten and casein (milk protein) with GFCF diet
Description: Group I: will receive the control product (product containing gluten and casein) with the GFCF diet for the 2nd 6-weeks.~Group II: will receive the control product (product containing gluten and casein) with the GFCF diet for the 1st 6-weeks
Study: NCT00243867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxoprexin
Description: 6. Other events that, based upon appropriate medical judgement, may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxoprexin
Description: 6. Other events that, based upon appropriate medical judgement, may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes
Study: NCT01759342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flexibility and postural exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance exercise
Study: NCT03450239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI scan, including structural imaging, functional imaging (both task-related and structural), and Magnetic Resonance Spectroscopy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI scan, including structural imaging, functional imaging (both task-related and structural), and Magnetic Resonance Spectroscopy.
Study: NCT03902392

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NaturOx Group (A)
Description: Comparison between dietary supplement and placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group (B)
Description: Comparison between dietary supplement and placebo
Study: NCT03260907

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: The treatment is to be applied twice a week for acupuncture points(unilaterally at CV3, CV4, GV20 and bilaterally at KI3, SP6), used for all the patients assigned to this group. Disposable, sterilized, filiform acupuncture needles manufactured is to be used. An electric acupuncture device (CellMac STN-110, Stratek Co, Republic of Korea) will be connected to the CV3-CV4, KI3-SP6 acupoints and deliver stimulation with a 2-Hz frequency, asymmetric bimodal pulse, continuous wave mode, maximum intensity below the threshold (7.6\~13.9mA).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The treatment is to be applied twice a week for acupuncture points(unilaterally at CV3, CV4, GV20 and bilaterally at KI3, SP6), used for all the patients assigned to this group. Disposable, sterilized, filiform acupuncture needles manufactured is to be used.
Study: NCT00609453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Activation Treatment for Depression
Description: Weekly individual therapy sessions
Study: NCT04173299

Intervention type: PROCEDURE
Intervention: early tips
Description: patients with early tips
Study: NCT02030444

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET-MRI and EBUS-TBNA
Study: NCT01974336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid
Study: NCT00183937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS 341
Description: PS 341 1.6 mg/m2 IV (in the vein) on days 1 and 8 of each 21 day cycle up to 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 IV (in the vein) on day 1 of each 21 day cycle up to 12 cycles.
Study: NCT02470390

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Lazanda (nasal spray), Subsys (sub-lingual) and intravenous fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Lazanda (nasal spray), Subsys (sub-lingual) and intravenous fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Lazanda (nasal spray), Subsys (sub-lingual) and intravenous fentanyl
Study: NCT00573404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: will start at 200 mg daily and will be escalated up to 400 mg bid.If the 400 mg bid dose is tolerated, no further dose escalation will be performed. In the case of excessive toxicity on the starting dose, the option for de-escalation is provided. Sunitinib will start at 25 mg daily and if tolerated, will be escalated to 37.5 mg daily for subsequent dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT02175576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vanguard XP Bicruciate Knee System
Description: The Vanguard XP is a bicruciate retaining total knee design and is constrained by natural soft tissue.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vanguard CR Knee System
Description: The Vanguard CR system requires the ACL to be sacrificed and is constrained by soft tissue and device design.
Study: NCT01007942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Oral everolimus was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral everolimus placebo was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: intravenous vinorelbine (25 mg/m2 weekly)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vinorelbine
Description: intravenous vinorelbine (25 mg/m2 weekly)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: trastuzumab
Description: intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)
Study: NCT03565393

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Fibersol-2
Description: A placebo-controlled, randomized; double-blind 2 arm trial

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Fibersol-2
Description: A placebo-controlled, randomized; double-blind 2 arm trial
Study: NCT05209217

Intervention type: DRUG
Intervention: Ketamine
Description: Intranasal administration of their customary prescribed dose
Study: NCT00413686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7762
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: weekly intravenous infusion
Study: NCT04132583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflox®
Description: Participants received a single oral dose of 50 mg Deflox® tablet in either treatment period 1 or 2 under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflox®
Description: Participants received a single oral dose of 50 mg Deflox® tablet in either treatment period 1 or 2 under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cataflam DD®
Description: Participants received a single oral dose of 50 mg Cataflam DD® tablet in either treatment period 1 or 2 under fasting conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cataflam DD®
Description: Participants received a single oral dose of 50 mg Cataflam DD® tablet in either treatment period 1 or 2 under fasting conditions.
Study: NCT02972918

Intervention type: DRUG
Intervention: Levosimendan
Description: 24h preoperative infusion of levosimendan (0,1 mcg/Kg/min)
Study: NCT02502773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxethyl starch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxethyl starch